Abstracts tagged "Fatigue"

Abstract Number: 1242 • ACR Convergence 2020
Transcranial Direct Current Stimulation for Fatigue in Patients with Sjogren’s Syndrome: A Randomized, Double-blind Pilot Study
Ana Pinto¹, Sara Piva², Alexia Vieira³, Samantha Gomes³, Aline Rocha⁴, Daniela Tavares³, Marcia Santana³, Cristiane Carlesso⁵, Adagmar Andriolo³, Fania Santos⁶, Felipe Fregni⁷ and Virginia Trevisani³, ¹Universidade Federal do Amapa, Sao Paulo, Brazil, ²Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ³Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ⁴Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ⁵University of Pittsburgh, Pittsburgh, ⁶Universidade Federal de Sao Paulo, Sao Paulo, Saint Helena, ⁷Harvard Medical School, Cambridge, MA
Background/Purpose: Transcranial direct-current stimulation (tDCS) has shown promise to decrease fatigue. However, it has never been examined in primary Sjogren Syndrome (pSS). We aimed to assess…
Abstract Number: 1243 • ACR Convergence 2020
Self-reported Fatigue in Patients with Primary Sjögren’s Syndrome Is Associated with an Objective Decline in Physical Performance and Symptoms of Pain and Depression
Roeland Prak¹, Suzanne Arends², Greetje van Zuiden¹, Frans Kroese¹, Hendrika Bootsma¹ and Inge Zijdewind¹, ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: Fatigue is a major complaint in autoimmune diseases including primary Sjögren’s syndrome (pSS). For many pSS patients, fatigue is their most dominant and disabling…
Abstract Number: 1314 • ACR Convergence 2020
Fatigue in Psoriatic Arthritis (PsA): Prevalence in Patients from the US and Europe, and Impact on Quality of Life and Work Productivity
Jessica Walsh¹, Kaleb Michaud², Elizabeth Holdsworth³, Steven Peterson⁴, Nicola Booth³, Sophie Meakin³, Soumya Chakravarty⁵, James Piercy³ and Alexis Ogdie⁶, ¹University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ²University of Nebraska Medical Center, Omaha, NE, ³Adelphi Real World, Bollington, United Kingdom, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁶Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Fatigue is an important aspect of PsA for patients. Understanding the impact of fatigue on patient reported outcomes is important for effective management of…
Abstract Number: 1315 • ACR Convergence 2020
Exploring the Prevalence and Factors Associated with Fatigue in Axial Spondyloarthritis in a Multiethnic Asian Cohort in Singapore
Wei Ze Lim¹, Warren Fong², Yu Heng Kwan³ and Ying Ying Leung², ¹Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Singapore, ²Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, Singapore, ³Duke-NUS Medical School, Singapore, Singapore, Singapore
Background/Purpose: Fatigue is a cardinal symptom of axial spondyloarthritis (axSpA) that poses management challenges. Data on fatigue amongst Asian patients with axSpA is limited. Ethnicity…
Abstract Number: 0134 • ACR Convergence 2020
The Impact of Exercise on Sleep in People with Rheumatoid Arthritis: A Pilot Randomised Controlled Trial
Sean McKenna¹, Laura Comber², Alan Donnelly³, Alexander Fraser⁴, Bente Appel Esbensen⁵ and Norelee Kennedy³, ¹University of Limerick, Mallow, Cork, Ireland, ²HIQA, Limerick, Limerick, Ireland, ³University of Limerick, Limerick, Limerick, Ireland, ⁴University College Limerick, Limerick, Limerick, Ireland, ⁵University of Copenhagen, Glostrup, Hovedstaden, Denmark
Background/Purpose: Poor sleep quality and reduced sleep duration are prevalent complaints in people with RA. These in turn may further deteriorate functional ability and reduce…
Abstract Number: 1340 • ACR Convergence 2020
Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study
Helena Marzo-Ortega¹, Atul Deodhar², Ricardo Blanco³, Hideto Kameda⁴, Alan Kivitz⁵, Denis Poddubnyy⁶, Marina Magrey⁷, Jianyuan Wang⁸, Sibylle Haemmerle⁸, Abhijit Shete⁸ and Juergen Braun⁹, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²Oregon Health & Science University, Portland, OR, ³Hospital University Marqués de Valdecilla, Santander, Spain, ⁴Toho University, Tokyo, Japan, ⁵Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁷Case Western Reserve University School of Medicine, Cleveland, OH, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany
Background/Purpose: Patients with non-radiographic axial spondyloarthritis (nr-axSpA) suffer from comparable disease burden to patients with ankylosing spondylitis/radiographic axSpA (AS/r-axSpA), including inflammatory back pain, morning stiffness,…
Abstract Number: 0246 • ACR Convergence 2020
Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms
Rory Monahan¹, Rolf Fronczek¹, Jeroen Eikenboom¹, Huub Middelkoop¹, Liesbeth Beaart-van de Voorde¹, Gisela Terwindt¹, Nic van der Wee¹, Thomas Huizinga¹, Margreet Kloppenburg¹ and Margreet Steup-Beekman¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Fatigue is commonly described in chronic illnesses, especially in auto-immune disorders such as systemic lupus erythematosus (SLE). We aim to study the prevalence of…
Abstract Number: 1727 • ACR Convergence 2020
Patterns of Fatigue in Early RA over 10 Years: Results from the ESPOIR Cohort
Samantha Rodriguez-Muguruza¹, Bernard Combe², Oliver Valero³, Francis Guillemin⁴, Alejandro Olivé-Marqués⁵, Bruno Fautrel⁶, Ramon Fontova¹ and Cédric Lukas⁷, ¹Joan XXIII Hospital, Tarragona, Spain, ²University of Montpellier, Montpellier, France, ³Department of Statistics, Autonoma de Barcelona University, Barcelona, Spain, ⁴Universite de Lorraine CIC INSERM, Nancy, France, ⁵Hospital Germans Trias i Pujol, Barcelona, Spain, ⁶Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁷CHU Montpellier and University of Montpellier, Montpellier, France
Background/Purpose: to determine and characterize fatigue trajectories over 10 years of follow-up in a cohort of early RA patients. Methods: We selected patients fulfilling the 2010…
Abstract Number: 0273 • ACR Convergence 2020
Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia
Jennifer Rogers¹, Megan Clowse², Lisa Criscione-Schreiber³, Jayanth Doss⁴, Rebecca Sadun⁴, Kai Sun⁵ and Amanda Eudy⁴, ¹Duke, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University Hospital, Durham
Background/Purpose: Patients with SLE have poor health related quality of life (HRQoL), however the differences in the predominant causes of decreased HRQoL across subgroups of…
Abstract Number: 1735 • ACR Convergence 2020
Effect of Aerobic Land-based Exercise Intervention on Fatigue in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Samar Aboulenain¹, Arezo Farhangi², Elie Donath¹ and Ozlem Pala³, ¹University of Miami Miller School, West Palm Beach, FL, ²University of Miami Miller School, Palm Beach Gardens, FL, ³University of Miami Miller School, Fort Lauderdale, FL
Background/Purpose: Persistent fatigue can be debilitating for patients with rheumatoid arthritis (RA). Although fatigue partially improves after the initiation of DMARDs, suggesting an inflammatory process,…
Abstract Number: 0276 • ACR Convergence 2020
Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy
Raeann Whitney¹, Amanda Eudy², Cynthia Coffman³, Megan Clowse⁴, Lisa Criscione-Schreiber⁵, Jayanth Doss², Rebecca Sadun², Kai Sun² and Jennifer Rogers⁶, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC, ³Duke University, Durham, ⁴Duke University, Chapel Hill, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke, Durham, NC
Background/Purpose: Management of Type 2 SLE (widespread pain, fatigue, depression, sleep distrubance, and cognitive dysfunction) is challenging and often requires multiple medications to ameliorate symptoms.…
Abstract Number: 1737 • ACR Convergence 2020
What Influences Fatigue Improvement in Rheumatoid Arthritis? A Prospective Cohort Study
Samar Aboulenain¹, Elie Donath¹ and Ozlem Pala², ¹University of Miami Miller School, West Palm Beach, FL, ²University of Miami Miller School, Fort Lauderdale, FL
Background/Purpose: Fatigue is a common and debilitating complication in patients with rheumatoid arthritis (RA). Its mechanism is not fully elucidated, and when persistent is often…
Abstract Number: 0347 • ACR Convergence 2020
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
Proton Rahman¹, Philip Helliwell², Atul Deodhar³, Alexa Kollmeier⁴, Elizabeth Hsia⁵, Bei Zhou⁶, Xiwu Lin⁶, Chenglong Han⁶ and Philip Mease⁷, ¹Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Janssen Research & Development, LLC, La Jolla, CA, ⁵Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2 are phase-3 trials of guselkumab (GUS, an IL-23 inhibitor) in patients with psoriatic arthritis (PsA). In both trials, treatment with…
Abstract Number: 1838 • ACR Convergence 2020
Aerobic Exercise Improves Fatigue and Quality of Life in Women with Systemic Lupus Erythematosus (Preliminary Analysis)
Marquis Chapman¹, Sarthak Gupta¹, Jun Chu¹, Mohammad Naqi¹, Zerai Manna², Mir Ali Mazhar¹, Adam Munday¹, Marybeth Stockman¹, Anam Ahmad¹, Gayle McCrossin¹, Bart Drinkard¹, Lisa Chin¹, Mariana Kaplan³, Randall Keyser¹, Leighton Chan¹ and Sarfaraz Hasni², ¹National Institutes of Health, Bethesda, MD, ²Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease of female predominance. One of the most debilitating symptoms experienced by SLE-patients is persistent…
Abstract Number: 0906 • ACR Convergence 2020
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
Atul Deodhar¹, Laure Gossec², Philip Mease³, Jason Coarse⁴, Heather Edens⁵, Natasha de Peyrecave⁶, Deepak Assudani⁶, Barbara Ink⁷ and Christopher Ritchlin⁸, ¹Oregon Health & Science University, Portland, OR, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Slough, ⁸Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…

« Previous Page
1
…
5
6
7
8
9
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].